Menopause The Journal of The North American Menopause Society · 2009 · 122 citations · 15 references
PharmacyGynecologyPharmacotherapyReproductive MedicineWomen's HealthWomen's Health PharmacotherapyMenopause Hormone TherapyVaginal DisordersVaginal Dosage FormsOpen-label PlaceboTransvaginal Ultrasound FindingsVaginal Atrophy AssessmentVaginal Atrophy TreatmentVaginal CreamsVaginal DrynessVulvovaginal AtrophyVulvovaginal Dryness
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of low-dose conjugated estrogens (CE) cream for treatment of atrophic vaginitis. METHODS: Postmenopausal women (N = 423) with moderate-to-severe vaginal atrophy were randomized to CE cream 0.3 mg or placebo once daily (21 days on/7 days off) or twice weekly for 12 weeks, followed by open-label treatment with CE cream for 40 weeks consistent with their prior regimen. Primary endpoints were changes in vaginal maturation index (VMI; percentage of superficial cells), vaginal pH, and severity of participant-reported most bothersome symptom (vaginal dryness, itching, burning, or dyspareunia) at week 12. Endometrial safety was assessed by transvaginal ultrasound and endometrial biopsy for 52 weeks. RESULTS: At week 12, improvements in VMI with daily and twice-weekly use of low-dose CE cream (27.9% and 25.8%, respectively) were significantly greater compared with placebo (3.0% and 1.0%, respectively; P < 0.001). Improvements in vaginal pH with daily and twice-weekly CE cream (-1.6 for both) were also significantly greater relative to placebo (-0.4 and -0.3, respectively; P < 0.001). VMI and vaginal pH responses were sustained through 52 weeks. Both CE cream regimens significantly reduced most bothersome symptom scores compared with placebo (P < or = 0.001), including those for dyspareunia (P < or = 0.01). There was no report of endometrial hyperplasia or carcinoma. Adverse events occurred with similar frequency among the active and placebo groups during the double-blind phase. CONCLUSIONS: Daily and twice-weekly use of low-dose CE cream was equally effective in relieving symptoms of vulvovaginal atrophy. Both regimens showed endometrial safety and sustained efficacy during 1 year of therapy.
15
Kristen B. Levine, Rachel E. Williams, Katherine E. Hartmann · Menopause The Journal of The North American Menopause Society · 2008 · 294 citations
Medicine, Endocrinology, Gynecology +17
Diagnosis and treatment of atrophic vaginitis.
Gloria Bachmann, Nicole Nevadunsky · PubMed · 2000 · 292 citations
Medicine, Endocrinology, Gynecology +12
The Detection and Management of Vaginal Atrophy
Shawna Johnston, Scott A. Farrell, Céline Bouchard et al. · Journal of Obstetrics and Gynaecology Canada · 2004 · 148 citations
Medicine, Gynecology, Obstetrics +12